Mutual Advisors’s GSK GSK Stock Holding History

Mutual Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	20,887 +236	+1%	+$12.5K	0.02%	618
2026 Q1	$1.14M	Sell	20,651 -170	-0.8%	-$9.21K	0.02%	544
2025 Q4	$1.02M	Buy	20,821 +3,848	+23%	+$179K	0.02%	570
2025 Q3	$773K	Buy	16,973 +368	+2%	+$14.4K	0.02%	671
2025 Q2	$630K	Buy	16,605 +2,762	+20%	+$106K	0.02%	677
2025 Q1	$518K	Buy	13,843 +5	+0%	+$183	0.01%	692
2024 Q4	$463K	Sell	13,838 -423	-3%	-$15.2K	0.01%	727
2024 Q3	$538K	Sell	14,261 -4,887	-26%	-$200K	0.02%	676
2024 Q2	$766K	Buy	19,148 +6,869	+56%	+$289K	0.02%	569
2024 Q1	$526K	Buy	12,279 +2,175	+22%	+$89.7K	0.02%	678
2023 Q4	$374K	Buy	10,104 +452	+5%	+$16.2K	0.01%	747
2023 Q3	$350K	Sell	9,652 -443	-4%	-$15.7K	0.01%	726
2023 Q2	$360K	Sell	10,095 -12,569	-55%	-$451K	0.01%	742
2023 Q1	$806K	Sell	22,664 -3,141	-12%	-$110K	0.03%	488
2022 Q4	$907K	Buy	25,805 +727	+3%	+$24.2K	0.04%	432
2022 Q3	$738K	Sell	25,078 -1,180	-4%	-$44.7K	0.04%	453
2022 Q2	$1.43M	Buy	26,258 +6,775	+35%	+$374K	0.09%	253
2022 Q1	$1.06M	Buy	19,483 +2,961	+18%	+$161K	0.06%	358
2021 Q4	$911K	Buy	16,522 +5,825	+54%	+$303K	0.05%	412
2021 Q3	$511K	Buy	10,697 +2,978	+39%	+$150K	0.03%	534
2021 Q2	$384K	Buy	7,719 +2,761	+56%	+$133K	0.02%	614
2021 Q1	$221K	Sell	4,958 -476	-9%	-$21.6K	0.02%	704
2020 Q4	$250K	Sell	5,434 -31	-0.6%	-$1.42K	0.02%	644
2020 Q3	$257K	Buy	5,465 +407	+8%	+$20.4K	0.02%	575
2020 Q2	$258K	Buy	5,058 +455	+10%	+$23.3K	0.03%	538
2020 Q1	$218K	Sell	4,603 -409	-8%	-$21.8K	0.03%	476
2019 Q4	$294K	Buy	5,012 +653	+15%	+$36.3K	0.03%	467
2019 Q3	$233K	Buy	+4,359	New	+$224K	0.03%	470
2018 Q2	–	Sell	-5,657	Closed	-$276K	–	426
2018 Q1	$276K	Buy	+5,657	New	+$263K	0.07%	323

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mutual Advisors's GSK Position: Q2 2026 in Review

Mutual Advisors increased its GSK (GSK) stake by 1.1% in Q2 2026, buying an estimated $12.5K and bringing the position to 20,887 shares worth $1.09M. The position accounts for 0.02% of the portfolio, ranked #618.

Mutual Advisors first reported a position in GSK in Q1 2018 and has held it in 29 quarters since. The position peaked at $1.43M in Q2 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Mutual Advisors held 20,887 shares of GSK worth $1.09M as of Q2 2026.
Mutual Advisors bought 236 GSK shares in Q2 2026, an estimated $12.5K.
GSK made up 0.02% of Mutual Advisors's portfolio in Q2 2026, its #618 holding.
Mutual Advisors first reported a position in GSK in Q1 2018 and has held it in 29 quarters since.
Mutual Advisors's GSK position peaked at $1.43M in Q2 2022.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Mutual Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.